Symposium
Thu. May 20, 2021 4:15 PM - 6:15 PM Room 01 (ICC Kyoto 1F Main Hall)
Chair：Nakahara Jin(Department of Neurology, Keio University School of Medicine),Fujii Chihiro(Department of Neurology, University Hosiptal Kyoto Prefectural University of Medicine)
Since early 2000s, anti-AQP4 antibodies and anti-MOG antibodies have emerged as specific biomarkers for "seropositive" and "seronegative" NMOSD, respectively. Nowadays, several clinical phenotypes have also been shown to be associated with the latter antibodies, segregating "MOG-related disorders". This symposium aims to share and discuss the information about cutting-edge advances in NMOSD and MOG-related disorders, with respect to both treatment and research.
○Masato Yasui (Department of Pharmacology, Keio University School of medicine, Japan)
Schedule
Like
)
○Noriko Isobe (Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Japan)
Schedule
Like
)
○Kazuo Fujihara1,2 (1.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Japan, 2.Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan)
Schedule
Like
)
○Yoshiki Takai1, Tatsuro Misu1, Kazuo Fujihara1,2, Masashi Aoki1 (1.Department of Neurology, Tohoku University School of Medicine, Japan, 2.Department of multiple sclerosis therapeutics, Fukushima Medical University School of Medicine)
Schedule
Like
)
○Sung Min Kim (Department of Neurology, Seoul National University Hospital, Korea)
Schedule
Like
)